基于Omicron的COVID-19疫苗候选人的临床试验竞赛:来自全球数据库的更新
Sandro G Viveiros-Rosa1, Cristina Ds Mendes1, Galo G Farfán-Cano2
1National Institute of Industrial Property, Rio de Janeiro, Brazil.
Narra J
|March 7, 2024
概括
针对Omicron变种的新型COVID-19疫苗正在开发中. 不活化和mRNA疫苗的临床试验正在进行中,预计将在2023年取得结果,以指导未来的强剂量.
科学领域:
- * 疫苗学和病毒学
- * 传染病流行病学
背景情况:
- * 严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 的Omicron变种具有很高的传染性,即使在接种疫苗的个体中也可能引起严重的疾病.
- * 目前的疫苗,主要针对野生型菌株,对Omicron的疗效降低,需要更新的疫苗配方.
研究的目的:
- *审查和分析正在进行的针对专门针对SARS-CoV-2 Omicron变种设计的COVID-19疫苗的临床试验.
- *为研究人员和政策制定者提供关于Omicron特定疫苗的开发状态和未来方向的见解.
主要方法:
- * 在国际平台上注册的临床试验的全面搜索和分析.
- *截至2022年6月10日,数据收集主要集中在疫苗类型 (无活化和mRNA) 和试验状态上.
主要成果:
- *截至2022年6月10日,已经确定了15项临床试验,评估了四种无活化和四种mRNAOmicron特定疫苗候选人.
- * 美国和英国的两种针对Omicron的疫苗 (Pfizer,Moderna) 已获得紧急使用授权.
- * 几家亚洲制药公司 (CNBG,Sinovac,Shifa Pharmed) 正在进行第三阶段试验,大多数预计将于2023年完成.
结论:
- *由于现有疫苗的疗效下降,开发针对Omicron的COVID-19疫苗至关重要.
- *正在进行的临床试验显示出有前途的进展,几名候选人即将完成.
- *研究结果将为对抗不断发展的SARS-CoV-2 Omicron变种的更新后剂量进行战略投资提供信息.
更多相关视频
相关概念视频
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...


